[(18)F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer: a systematic review and meta-analysis
- PMID: 24334433
- PMCID: PMC3864168
- DOI: 10.1102/1470-7330.2013.0038
[(18)F]Fluorodeoxyglucose-positron emission tomography screening for lung cancer: a systematic review and meta-analysis
Abstract
Rationale and objectives: Although low-dose computed tomography (CT) is a recommended modality for lung cancer screening in high-risk populations, the role of other modalities, such as [(18)F]fluorodeoxyglucose-positron emission tomography (PET), is unclear. We conducted a systematic review to describe the role of PET in lung cancer screening.
Materials and methods: A systematic review was conducted by reviewing primary studies focusing on PET screening for lung cancer until July 2012. Two independent reviewers identified studies that were compatible for inclusion/exclusion criteria. The analysis was restricted to English and included studies published since 2000. A descriptive analysis was used to summarize the results, and the pooled diagnostic performance of selective PET screening was calculated by weighted average using individual sample sizes.
Results: Among the identified studies (n = 3497), 12 studies were included for analysis. None of the studies evaluated the efficacy of primary PET screening specific to lung cancer. Eight studies focused on primary PET screening for all types of cancer; the detection rates of lung cancer were low. Four studies reported evidence of lung cancer screening programs with selective PET, in which the estimated pooled sensitivity and specificity was 83% and 91%, respectively.
Conclusions: The role of primary PET screening for lung cancer remains unknown. However, PET has high sensitivity and specificity as a selective screening modality. Further studies must be conducted to evaluate the use of PET or PET/computed tomography screening for high-risk populations, preferably using randomized trials or prospective registration.
Advances in knowledge: Our meta-analysis indicates that PET has high sensitivity and specificity as a selective screening modality.
Figures




Similar articles
-
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350. Health Technol Assess. 2011. PMID: 21958472 Free PMC article.
-
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.Cochrane Database Syst Rev. 2021 Nov 9;11(11):CD012325. doi: 10.1002/14651858.CD012325.pub2. Cochrane Database Syst Rev. 2021. PMID: 34753195 Free PMC article.
-
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.Cochrane Database Syst Rev. 2015 Jan 9;1(1):CD010533. doi: 10.1002/14651858.CD010533.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2025 Mar 26;3:CD010533. doi: 10.1002/14651858.CD010533.pub3. PMID: 25572491 Free PMC article. Updated.
-
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2. Cochrane Database Syst Rev. 2015. PMID: 25629415 Free PMC article.
-
Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.Cochrane Database Syst Rev. 2022 Aug 3;8(8):CD013829. doi: 10.1002/14651858.CD013829.pub2. Cochrane Database Syst Rev. 2022. PMID: 35921047 Free PMC article.
Cited by
-
Differentiation between staple line granuloma and recurrence after sublobar resection for primary lung cancer.J Thorac Dis. 2022 Jan;14(1):26-35. doi: 10.21037/jtd-21-1626. J Thorac Dis. 2022. PMID: 35242365 Free PMC article.
-
Diagnostic Performance of PET or PET/CT with Different Radiotracers in Patients with Suspicious Lung Cancer or Pleural Tumours according to Published Meta-Analyses.Contrast Media Mol Imaging. 2020 Apr 25;2020:5282698. doi: 10.1155/2020/5282698. eCollection 2020. Contrast Media Mol Imaging. 2020. PMID: 32405280 Free PMC article. Review.
-
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature.Life (Basel). 2023 Aug 28;13(9):1821. doi: 10.3390/life13091821. Life (Basel). 2023. PMID: 37763225 Free PMC article. Review.
-
Local Intratracheal Delivery of Perfluorocarbon Nanoparticles to Lung Cancer Demonstrated with Magnetic Resonance Multimodal Imaging.Theranostics. 2018 Jan 1;8(2):563-574. doi: 10.7150/thno.21466. eCollection 2018. Theranostics. 2018. PMID: 29290827 Free PMC article.
References
-
- NCCN clinical practice guidelines in oncology: Lung Cancer Screening 2013.v.1. Available from : http://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf (accessed 11 July 2012)
-
- MacManus M, Hicks RJ. The use of positron emission tomography (PET) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: a critical review. Int J Radiat Oncol Biol Phys. 2008;72:1298–1306. doi: 10.1016/j.ijrobp.2008.08.022. PMid: 19028270. - PubMed
-
- Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol. 2010;5:612–619. doi: 10.1097/ JTO. 0b013e3181d0a4f5. PMid: 20234323. - PubMed
-
- Kligerman S, Digumarthy S. Staging of non-small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol. 2009;193:1203–1211. doi: 10.2214/AJR.09.3193. PMid: 19843732. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical